All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and ...

Fate Therapeutics (FATE) presented new clinical and translational data from the company’s FT819 Phase 1 Autoimmunity study for ...

Stem cells in the intestine can adjust their function by using PIEZO channels that sense extracellular forces and activate ...

On the outskirts of Sednaya prison, known as Syria’s “human slaughterhouse,” a hidden underground complex was uncovered, ...

Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc.

DAMASCUS - When she heard the stunning news that rebels had brought an end to Syria's decades-old regime, Hayat al-Turki ...

(NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with ...

Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and ...

The U.S. has identified prisons of interest as it searches for clues about Austin Tice, who was abducted in 2012 and whose ...